Provided are indazole-3-carboxamide derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 5-(Pyridin-3-yl)-N-(pyridin-4-yl)-1H-indazole-3-carboxamide and N-(6-carbamoylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide. The compounds are Wnt/&bgr-catenin signalling pathway inhibitors and may be useful in the treatment of various diseases associated with the aforementioned pathway including cancer.